Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for ATNM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 30.30M
March 31, 2026 2.304M
December 31, 2025 7.834M
September 30, 2025 13.78M
June 30, 2025 19.01M
March 31, 2025 25.69M
December 31, 2024 32.76M
September 30, 2024 38.21M
June 30, 2024 43.84M
March 31, 2024 43.86M
December 31, 2023 36.38M
September 30, 2023 43.58M
June 30, 2023 53.08M
March 31, 2023 57.21M
December 31, 2022 66.48M
September 30, 2022 71.26M
June 30, 2022 78.18M
March 31, 2022 68.84M
December 31, 2021 73.54M
September 30, 2021 80.28M
June 30, 2021 80.50M
March 31, 2021 70.74M
December 31, 2020 61.32M
September 30, 2020 45.43M
June 30, 2020 50.77M
Date Value
March 31, 2020 3.02M
December 31, 2019 5.644M
September 30, 2019 9.936M
June 30, 2019 15.70M
March 31, 2019 5.343M
December 31, 2018 8.813M
September 30, 2018 11.58M
June 30, 2018 17.32M
March 31, 2018 21.75M
December 31, 2017 13.67M
September 30, 2017 18.19M
June 30, 2017 8.871M
March 31, 2017 12.88M
December 31, 2016 18.01M
September 30, 2016 14.23M
June 30, 2016 19.08M
March 31, 2016 20.06M
December 31, 2015 21.97M
September 30, 2015 22.89M
June 30, 2015 23.28M
March 31, 2015 16.44M
December 31, 2014 -1.922M
September 30, 2014 2.372M
June 30, 2014 4.33M
March 31, 2014 -13.47M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics